Back to 
AssetMark, Inc.
AssetMark, Inc.
ERNA
2 quarters
Position history for AssetMark, Inc.'s holdings in Ernexa Therapeutics Inc.
Yes. AssetMark holds 5 shares of ERNA (Ernexa Therapeutics), worth $16, as of its Q3 2026 13F filing. The share count is unchanged from Q2 2026. AssetMark has held ERNA since Q2 2026, across 2 quarterly 13F filings.
Current Value
$16
Current Shares
5
Total Value Change
-$17
Total Shares Change
0
Quarter-by-Quarter History
Other major holders of ERNA: Citadel Advisors LLC, Vanguard Fiduciary Trust Co., Geode Capital Management, LLC, Vanguard Capital Management LLC, Citigroup Inc.